molnupiravir: Clinical Trials

11 trials of molnupiravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 recruiting, 1 terminated. 11 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 5, Recruiting 5, Terminated 1
Phase 33Completed 2, Terminated 1
Phase 11Recruiting 1

Follow molnupiravir: new trials by email Literature Review of molnupiravir trials Research Report on molnupiravir

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Dengue Antiviral Platform Trial
Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs
Phase 2RecruitingOxford University Clinical Research Unit, Vietnam5002026-04-202026-09-28
Assessing Antiviral Treatments in Early Symptomatic RSV
Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
Phase 2RecruitingUniversity of Oxford10002024-07-252025-07-02
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human
Phase 2RecruitingUniversity of Oxford30002023-02-222026-04-14
Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
Molnupiravir, Placebo, RSV A Memphis 37b - Respiratory Syncytial Virus
Phase 2CompletedMerck Sharp & Dohme LLC1162022-11-022025-07-18
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
Molnupiravir 200 mg - COVID-19
Phase 2 / Phase 3CompletedUniversity of Witwatersrand, South Africa592022-08-122025-07-01
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19
Phase 2RecruitingUniversity of Oxford38002021-09-302026-02-19
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
Molnupiravir, Placebo - Coronavirus Disease (COVID-19)
Phase 2 / Phase 3TerminatedMerck Sharp & Dohme LLC3042020-10-192023-01-17
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
Molnupiravir, Placebo - Coronavirus Disease (COVID-19)
Phase 2 / Phase 3CompletedMerck Sharp & Dohme LLC17352020-10-192023-06-28
AGILE (Early Phase Platform Trial for COVID-19)
CST-2: EIDD-2801, CST-2: Placebo, Nitazoxanide - Covid19
Phase 1 / Phase 2RecruitingUniversity of Liverpool6002020-07-032026-06-01
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg - SARS-CoV-2 Infection, COVID-19
Phase 2CompletedRidgeback Biotherapeutics, LP2042020-06-192022-02-16
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
EIDD-2801, Placebo - SARS-CoV 2
Phase 2CompletedRidgeback Biotherapeutics, LP712020-06-162023-03-23

Conditions studied

COVID-19 (6)  ·  Dengue (1)  ·  Influenza, Human (1)

Sponsors

Merck Sharp & Dohme LLC (3)  ·  University of Oxford (3)  ·  Ridgeback Biotherapeutics, LP (2)  ·  Oxford University Clinical Research Unit, Vietnam (1)  ·  University of Liverpool (1)  ·  University of Witwatersrand, South Africa (1)

Countries

Brazil (4)  ·  South Africa (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Laos (3)  ·  Thailand (3)  ·  Canada (2)  ·  Chile (2)  ·  Colombia (2)  ·  France (2)  ·  Israel (2)  ·  Italy (2)  ·  Mexico (2)  ·  Nepal (2)  ·  Philippines (2)

Top investigators

Ashwin Balagopal, MD (1)  ·  Francois WD Venter (1)  ·  Saye Khoo (1)  ·  Sophie Yacoub, MD., PhD. (1)

Results publications

PMID 33273742, PMID 34100024, PMID 34159342, PMID 34450619, PMID 34473343, PMID 34699618, PMID 34914868, PMID 35022711, PMID 35271729, PMID 35667065, PMID 36272432, PMID 36435798, PMID 36648627, PMID 36803992, PMID 37017631, PMID 37466374, PMID 37470445, PMID 37778363, PMID 37995070, PMID 38225598, PMID 38319178, PMID 38319179, PMID 38677300, PMID 39896880, PMID 40025641, PMID 40175624, PMID 41082886, PMID 41125063, PMID 41321979, PMID 41848748, PMID 42520824